DelveInsight Releases Tradipitant Market Forecast and Analysis

Market research firm DelveInsight has released a comprehensive report detailing the market forecast and insights for Tradipitant, a drug being developed to treat various conditions involving nausea and vomiting. The report projects market performance through 2034, highlighting its potential applications in areas such as motion sickness, gastroparesis, and managing side effects of GLP-1 medications.

Tradipitant is an oral neurokinin-1 (NK1) receptor antagonist designed to block substance P, a neurotransmitter implicated in the pathways controlling nausea and vomiting. This mechanism of action targets both the central nervous system and the gastrointestinal tract, aiming to reduce emetic signaling.

A significant growth driver identified in the report is Tradipitant's potential to mitigate nausea and vomiting associated with GLP-1 receptor agonists, commonly used for obesity and diabetes. Clinical studies have indicated a substantial reduction in vomiting episodes when Tradipitant is co-administered, which could improve patient adherence to these widely used therapies. The immense size of the GLP-1 market suggests a considerable opportunity for Tradipitant as an adjunct therapy.

The drug has also been investigated for gastroparesis, a condition characterized by delayed gastric emptying and severe nausea. Despite a past Complete Response Letter from the FDA for this indication, development is ongoing. Tradipitant received U.S. FDA approval in December 2025 for the prevention of vomiting due to motion sickness, marking a significant advancement in treating this common ailment.

The DelveInsight analysis covers Tradipitant's market size, sales projections, and competitive landscape across key regions including the United States, Japan, and the EU4 countries plus the UK. It provides details on the drug's mechanism of action, dosage, and its commercial potential across different therapeutic areas.